Navigation Links
FDA Approves New Treatment for People With COPD
Date:8/1/2014

FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with the progressive, deadly respiratory ailment known as chronic obstructive pulmonary disease (COPD) have a new weapon to battle the disease, the U.S. Food and Drug Administration said Thursday.

The agency approved a new treatment, an inhaled spray called Striverdi Respimat (olodaterol) for COPD, the third leading killer of Americans. COPD, which is often linked to smoking, involves multiple lung conditions such as chronic bronchitis and emphysema.

Patients with COPD may experience a number of symptoms, such as wheezing, coughing and tightness in their chest. According to the FDA, Striverdi Respimat belongs to a class of medicines known as long-acting beta-adrenergic agonists (LABAs).

The agency said the drug works by helping the airway muscles in the lungs stay relaxed, and it can be taken once daily over a prolonged period of time.

"The availability of this new long-term maintenance medication provides an additional treatment options for the millions of Americans who suffer with COPD," Dr. Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

The FDA evaluated the safety and effectiveness of Striverdi Respimat compared to a placebo in more than 3,100 people diagnosed with COPD. Those who took the medication had improved lung function.

Commonly reported side effects of Striverdi Respimat include runny nose, coughs, dizziness and upper respiratory tract infections, among others.

Striverdi Respimat is not approved for people with asthma, and asthma patients should not use it, the FDA warned. That's because the drug raises the risk of asthma-related death. This inhalation spray should also never be used to treat breathing problems that develop suddenly, the agency cautioned.

People with COPD that is progressing rapidly should also not take Striverdi Respimat, the FDA added. For these patients, the medication could lead to heart problems and the narrowing or blockage of the airway, they explained.

More information

The U.S. National Heart, Lung, and Blood Institute provides more information on COPD treatments.

SOURCE: U.S. Food and Drug Administration, news release, July 31, 2014.

--


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Generic Versions of Plavix
2. FDA Approves Combo Shot for Meningitis, Hib in Kids
3. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
4. FDA Approves First New Weight-Loss Drug in More Than a Decade
5. FDA Approves 1st Pill to Help Prevent HIV Infection
6. FDA Approves 2nd New Weight-Loss Drug
7. FDA Approves Flu Vaccine for Coming Season
8. FDA Approves New Once-a-Day HIV Pill
9. FDA Approves New Type of Flu Vaccine
10. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
11. FDA Approves 1st Skin Patch to Combat Migraines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves New Treatment for People With COPD
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical Associates ... Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference ... providers an opportunity to learn about cutting edge treatments, to collaborate, share research ...
(Date:4/21/2017)... ... April 21, 2017 , ... Providing for loved ones before one’s passing is ... where to even begin. “Now more than ever there are some questions that are ... and your family,” said attorney Lisa Edgar Dickman, founder of the Law Offices of ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl says ... work because the plan is given by the Creator Himself. , Yisrayl says war ...
(Date:4/21/2017)... Texas (PRWEB) , ... April 21, 2017 , ... ... sound familiar? These are five common elements between the Obamacare program that ... hog control program which uses Warfarin poison to kill hogs. , Like ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
Breaking Medicine Technology: